Think about adding a personal story to the setup here…jenn was talking to some doctors about the technology and got the suggestion of ivig rather than oncology
Also add a set up on the technology
Who uses gammaglobulin?
Put the person first here
Didn’t really understand why anyone uses recombinant. We wanted to hear what patients had to say. Turns out what they think is actually pretty different from what doctors and pharmacists have to say.
Patients do care a lot about possible contamination. This stuff keeps them healthy, and they take it forever.
Talk about how IDF links together everything.
Talk about how IDF links together everything.
Talk about how IDF links together everything.
Talk about how production partners help you get over the hurdle you need to get over to get ANYWHERE.
Before we started, we didn’t understand who does what, and where, in the protein production industry. We certainly weren’t going to go out and build a 10,000 liter reactor ourselves.
We learned through our travels that we needed to go to EU for small and large scale GMP, because of their unique experience there with large scale protein production in yeast.
We would need to build our own protocols for protein libraries. Nobody has ever done this before, so it must be a technical focus. It’s also a huge opportunity that builds value in the company.
But how would we get our product to the customers? Drugs get to customers in pretty complicated ways.
We had a few hypotheses about how this might work for us.
This was one of the hardest areas to get information. It’s a real complex system, and very few people appear to comprehend the full system.
So we really needed to connect the dots! Talk about Mike – because he understands the the system.
We found that distributers and specialty pharma are really the way to go.But we still need to learn a lot more about how we should get our product to market, and how to get it paid for.
By the time we finished 163 interviews, we discovered that there was a whole ecosystem that we could leverage through the entire process, from protein production to clinical studies to human blood sample collection.
The process has helped us understand who to talk to, how much things will cost, and what will be the timelines to achieve particular tasks.
We are going hard a partnering at JP Morgan in January
We are going hard at raising Series A in 2015
We are going hard at following our Phase I grants with Phase II and executing strong on our Phase II grants.
Infectious Disease doctors were not all that excited about a recombinant IVIG replacement
But, they kept telling us that there is an opportunity to make specific pathogen-directed targeted IVIG
We will be speaking with dozens of stakeholders over the next month to explore whether this should be product 1!!
